CCR2 and diabetes mellitus: Ly6chi monocytes and Mo-MDSCs traffic from the bone marrow (BM) to sites of inflammation via CCR2-signaling [29], and therapeutic strategies based on CCR2-siRNA showed significant reduction in inflammatory monocyte effects in murine models of atherosclerosis, cancer, and diabetes [30].